17 March 2015Americas

Actavis completes $71bn acquisition of Allergan

Dublin-based pharmaceutical company Actavis has completed its acquisition of Allergan for $71 billion.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Allergan and Native American tribe in patent deal

11 September 2017 Allergan has transferred its patent rights for a dry eye treatment to a Native American tribe, in a bid to obtain immunity against an inter partes review (IPR).

Americas

Is the Allergan patent deal a misuse of sovereign immunity?

19 September 2017 Earlier this month, in a bid to obtain immunity against an inter partes review (IPR), Allergan transferred its patent rights for a dry eye treatment to a Native American tribe.

Big Pharma

Allergan’s Forest to face jury in antitrust suit over Alzheimer drug

15 June 2021 Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda, from the marketplace.

More on this story

Americas

Allergan and Native American tribe in patent deal

11 September 2017 Allergan has transferred its patent rights for a dry eye treatment to a Native American tribe, in a bid to obtain immunity against an inter partes review (IPR).

Americas

Is the Allergan patent deal a misuse of sovereign immunity?

19 September 2017 Earlier this month, in a bid to obtain immunity against an inter partes review (IPR), Allergan transferred its patent rights for a dry eye treatment to a Native American tribe.

Big Pharma

Allergan’s Forest to face jury in antitrust suit over Alzheimer drug

More on this story

Americas

Allergan and Native American tribe in patent deal

11 September 2017 Allergan has transferred its patent rights for a dry eye treatment to a Native American tribe, in a bid to obtain immunity against an inter partes review (IPR).

Americas

Is the Allergan patent deal a misuse of sovereign immunity?

19 September 2017 Earlier this month, in a bid to obtain immunity against an inter partes review (IPR), Allergan transferred its patent rights for a dry eye treatment to a Native American tribe.

Big Pharma

Allergan’s Forest to face jury in antitrust suit over Alzheimer drug